A series of 7-hydroxy-2-[N-alkyl-(N-(4-phenylpiperazine)-alkyl) amino] tetralins was developed based on a novel hybrid approach that combined 2-aminotetralin and arylpiperazine pharmacophoric moieties. Our preliminary study revealed that a four- methylene butyl linker produced very potent compounds for both the D2 and D3 receptors. Further structure–activity studies led to a novel template showing 50-to 100-fold selectivity ...